Amazon Pharmacy now offers Novo Nordisk’s Wegovy as an oral weight‑loss pill, the first GLP‑1 medication of its class to be available in tablet form. The drug was approved by the FDA on December 22, 2025 and launched in the United States on January 5, 2026; Amazon announced the new offering on January 9, 2026.
The oral Wegovy is priced at $25 per month for patients with commercial insurance, while cash‑pay customers can purchase a one‑month supply of the starting dose for $149. Higher doses, which are required for sustained weight loss, are priced proportionally higher.
Amazon is integrating the new drug into its existing One Medical network by installing pharmacy kiosks at select One Medical clinics. The kiosks began rolling out in December 2025, and One Medical was acquired by Amazon in February 2023 for approximately $3.9 billion.
The U.S. obesity‑treatment market is projected to reach $30 billion by 2030, though other analyses estimate figures as high as $70 billion. Amazon expects the Wegovy launch to generate roughly $2 billion in annual revenue for Amazon Pharmacy, reinforcing its strategy to grow its health‑care business alongside retail and AWS.
Amazon’s move builds on a decade‑long healthcare strategy that began with the acquisition of PillPack in June 2018 and the launch of Amazon Pharmacy on November 17, 2020. “By offering Wegovy through both insurance and a straightforward cash‑pay option, we’re giving people more choice, greater transparency, and fewer barriers to care,” said Tanvi Patel, general manager of Amazon Pharmacy.
The addition of a high‑margin prescription drug gives Amazon a competitive edge in the online pharmacy market, leveraging its logistics network, data analytics, and large customer base. While competitors such as CVS and Walgreens also carry Wegovy, Amazon’s integrated One Medical kiosks and broad insurance coverage position it to capture a growing share of the obesity‑treatment market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.